Covered recipient · General Payments record
JOHN GAROFALO
General Payments · PY2018–2024
$1,779.96
- Reported across 88 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $213.47 | 9 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $91.97 | 4 |
| GENZYME CORPORATION | $36.36 | 1 |
| Regeneron Healthcare Solutions, Inc. | $35.87 | 1 |
| Biofrontera Inc. | $17.84 | 1 |
| Galderma Laboratories, L.P. | $15.99 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $15.44 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Biofrontera Inc. | $17.84 | 12/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111024443 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.17 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101784964 | CMS |
| E.R. Squibb & Sons, L.L.C. | $24.91 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101784990 | CMS |
| E.R. Squibb & Sons, L.L.C. | $24.98 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101785012 | CMS |
| E.R. Squibb & Sons, L.L.C. | $24.91 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101785038 | CMS |
| Galderma Laboratories, L.P. | $15.99 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145298934 | CMS |
| GENZYME CORPORATION | $36.36 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139600330 | CMS |
| Novartis Pharmaceuticals Corporation | $15.44 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086959461 | CMS |
| Regeneron Healthcare Solutions, Inc. | $35.87 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114053080 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.